Islet Sciences, Inc. is based in Raleigh, North Carolina and focused on improving patient outcomes by developing new medicines and technologies for the treatment of metabolic diseases including NASH and diabetes. The Company’s pipeline includes small molecule therapeutics, cell therapy based artificial pancreas, and a molecular diagnostic to detect the onset of insulin dependent diabetes. 

Islet Sciences, Inc. is developing new medicines and technologies for the treatment of metabolic disease. The Company is developing an encapsulated islet cell transplantation therapy for the treatment of insulin-dependent diabetes; first-in-class immune-modulating small molecule IL-12 inhibitors that protect insulin-producing beta-cells from cytokines responsible for cell destruction; and a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the diagnosis of type 1 diabetes or onset of insulin dependent type 2 diabetes. Upon effectiveness of a license executed in March 2015, Islet Sciences will also develop remogliflozin etabonate, an SGLT2 inhibitor in phase 2b for NASH and type 2 diabetes.


View Pipeline 

latest news

04.23.2015

Islet Sciences, Inc. Presented at 50th International Liver Conference  
VIEW PDF 

03.24.2015

Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum  
VIEW PDF 

03.09.2015

Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)  
VIEW PDF 

03.05.2015

Islet Sciences, Inc. Confirms Issuance of U.S. Patent for using SGLT2 inhibitors to treat NASH/NAFLD  
VIEW PDF 

03.03.2015

Islet Sciences Enters Into Exclusive License Agreement for Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate  
VIEW PDF 

11.20.2014

Islet Sciences CEO and COO interviewed on Radio In Vivo  
VIEW LINK 

10.23.2014
Islet Sciences and BHV Announce Publication of Two Phase 2b Clinical Studies of Remogliflozin Etabonate for Treating Type 2 Diabetes  
VIEW PDF 

10.06.2014
Islet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate  
VIEW PDF 

08.06.2014
Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors  
VIEW PDF 

07.16.2014
Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic  
VIEW PDF 

06.23.2014
Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)  
VIEW PDF 

06.16.2014
Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting  
VIEW PDF 

06.12.2014
Islet Sciences to Present SGLT2 Remogliflozin Phase 2b and Biphasic Formulation clinical data at American Diabetes Association (ADA)  
VIEW PDF 

05.29.2014
Islet Sciences Appoints Steven Delmar Chief Financial Officer 
VIEW PDF 

04.16.2014
Islet Sciences Anounces Positive Phase 2b Clinical Results for SGLT2 Inhibitor Remogliflozin 
VIEW PDF 

03.14.2014

Islet Sciences Anounces Dr. Michael Luther Appointed to Islet Sciences Board of Directors
View PDF
 

01.06.2014

Dr. Eric Barnett Appointed to Islet Sciences Board of Directors
View PDF
 

12.12.2013
Letter to shareholders from CEO James Green
View PDF
 

10.30.2013
Islet Sciences Appoints James Green as CEO and Dr. Bill Wilkison as COO

 

06.24.13
Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
READ MORE

05.10.13
Islet Sciences Article in Insulin Nation Titled “A Type 1 Triple Play”
READ MORE

05.07.13
Islet Sciences Highlights Abstract at Arteriosclerosis, Thrombosis & Vascular Biology ATVB 2013
READ MORE

04.29.13
Islet Sciences Reviews Japanese Patent Covering New Medication for Diabetes.
READ MORE

 

04.03.13
Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications for Treating Diabetes and other Serious Inflammatory Disorders
READ MORE

03.13.13
Islet Sciences Announces Important Study Published in Diabetes Titled “Immune Intervention Reducing β-Cell Death in Type 1 Diabetes”

READ MORE

Islet Sciences Announces Inclusion in BioWorld Today Article --- NEW YORK. NY, January 8, 2013 --Islet Sciences, Inc., (ISLT) a clinical stage...Learn More

Islet Sciences 6601 Six Forks Rd #140, Raleigh, NC 27615 Phone: 919.480.1518
Islet Sciences © 2011-2014 · Privacy Policy